The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS) DOI
Roger S. McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat

et al.

Expert Opinion on Drug Safety, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 6

Published: June 17, 2024

Introduction Replicated evidence indicates that ketamine and esketamine reduces measures of suicidality in persons with treatment resistant depression (TRD). It remains uncertain whether susceptible individuals may experience worsening pre-existing either agent.

Language: Английский

Effects of perioperative application of esketamine on postpartum depression in cesarean section: A systematic review and meta-analysis DOI Creative Commons
Baoyu Ma,

Xinyi Tao,

Yanyu Qi

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(27), P. e38821 - e38821

Published: July 5, 2024

Background: To evaluate the effect of perioperative esketamine administration on postpartum depression in pregnant women undergoing cesarean section. Methods: Data sources was PubMed, Embase, Web Science, and Cochrane Library from inception to February 1, 2024. Randomized controlled trials section were selected compared use period. The primary outcome measure incidence maternal depression. Preferred reporting items for systematic reviews meta-analyses used. pooled by random-effects models are presented as risk ratios (RR) (95% confidence intervals, 95% CI) or mean differences CI). This review registered PROSPERO (ID: CRD42023431197). Results: We included 8 studies with a total 1655 participants. quality rated high unclear. Seven involving 1485 participants reported Compared without esketamine, those using period showed 48% decreased developing (RR: 0.52, CI: 0.35–0.79) 1.43-point reduction EPDS (Edinburgh Postnatal Depression Scale) (mean difference: −1.43, −2.32 −0.54). For immediate intraoperative adverse reactions, application caused nausea vomiting 2.16, 1.22–3.81), dizziness 6.11, 1.49–24.98), hallucinations 6.83, 1.57–29.68) no use. Conclusions: Perioperative may reduce increase but has significant postoperative reactions.

Language: Английский

Citations

4
Data mining and analysis of adverse events of Vedolizumab based on the FAERS database DOI Creative Commons
Qun Xu, Jing Zhang, Weihong Tang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Jan. 2, 2025

Language: Английский

Citations

0
Comment on “Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis” DOI
Alina Wilkowska, Wiesław Jerzy Cubała

European Archives of Psychiatry and Clinical Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 22, 2025

Language: Английский

Citations

0
Is there a risk of esketamine misuse in clinical practice? DOI Creative Commons
Carlos Roncero, M. Merizalde Torres, Néstor Szerman

et al.

Therapeutic Advances in Drug Safety, Journal Year: 2025, Volume and Issue: 16

Published: Jan. 1, 2025

In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating remitting depressive symptoms, sustained benefits observed nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines strict medical supervision stem from prior research on ketamine's use depression history recreational drug. Despite initial concerns, long-term not documented instances abuse, misuse, addiction or withdrawal, same was found case reports subsamples high-risk populations comorbidities such substance disorder alcohol disorder. Esketamine has proven to be safe well tolerated without fostering new-onset vulnerable groups. Real-world reinforced these observations, reporting no adverse events (AEs) related pharmacological interactions any other substance, drug craving, misuse diversion use. Reports craving remain rare, only one report 2022. Most drug-related AEs reported pharmacovigilance databases are identified product's technical data sheet known frequency. More importantly, register illicit acquisition tampering obtaining ketamine altered products our search. Overall, review confirms safety across diverse patient populations, reassuring responsible scarcity abuse since introduction market.

Language: Английский

Citations

0
Adverse events analysis of Diroximel fumarate based on FAERS database DOI

Peipei Luan,

W. Xie,

Yuan Shen

et al.

Journal of the Neurological Sciences, Journal Year: 2025, Volume and Issue: 471, P. 123427 - 123427

Published: Feb. 16, 2025

Language: Английский

Citations

0
Increased Sensitivity to Psychomotor Effects of Ketamine Enantiomers in the Wistar-Kyoto Depression Model DOI Creative Commons
Kristian Elersič,

Anamarija Banjac,

Marko Živin

et al.

Journal of Psychiatric Research, Journal Year: 2025, Volume and Issue: 184, P. 307 - 317

Published: March 6, 2025

Ketamine, a fast-acting antidepressant, is racemic mixture, composed of equal amounts R- and S-ketamine. Preclinical studies are comparing them to better understand their role in therapeutic undesirable effects. An important research gap that do not use long clinically relevant protocols compare the desired undesired effects ketamine enantiomers modeled control animals. In our preclinical study, we explored behavioral S-ketamine at 10 mg/kg treatment protocol using Wistar-Kyoto rats as depression model Wistar control. Undesirable psychomotor were evaluated with locomotor stimulation sensitization, ataxia, stereotypy. Persistent associated outcomes by measuring working memory, anxiety, despair. We found has stronger acute compared R-ketamine more sensitive these rats. After repeated treatment, sensitization stimulating effects, tolerance ataxic develops. no persistent changes due treatments. Taken together, results may indicate depressed patients would be prone negative side ketamine, healthy controls. However, after develop make tolerable. Future clinical needed address neurobiological mechanisms relevance higher sensitivity development individuals.

Language: Английский

Citations

0
Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: A role of gut microbiota and metabolites DOI

Wei-Wei Luan,

Hanwen Gu,

Di Qiu

et al.

Neurochemistry International, Journal Year: 2025, Volume and Issue: 185, P. 105961 - 105961

Published: March 5, 2025

Language: Английский

Citations

0
Analysis and mining of Dupilumab adverse events based on FAERS database DOI Creative Commons
Gao Hui, Liqiang Cao, Chengying Liu

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 12, 2025

This study aims to explore potential adverse events (AEs) related Dupilumab using data from the US FDA Adverse Event Reporting System (FAERS) database. The FAERS database Q2 2017 Q4 2023 was mined for AEs Dupilumab. types of reported, along with gender, age distribution, and severity, were evaluated. Signal detection methods including Odds Ratio, Proportional Bayesian Confidence Propagation Neural Network, Empirical Geometric Mean used. A total 11,547,571 AE reports collected, 5335 suspected being Dupilumab, identifying 307 Preferred Terms involving 27 Organ Classes. Reports female patients outnumbered males (56.08% vs. 34.65%). Patients aged 45–65 years reported most (21.34%). number increased significantly in (34.25%) compared (0.42%), highest reporting rate (98.07%). Common included Pruritus, Product use unapproved indication, Rash, dose omission issue indicating widespread misuse High signal strength Rebound atopic dermatitis, eczema, Dermatitis atopic, Dry skin; injection site like Injection dryness eczema; new such as eye, Eye pruritus, Ocular hyperaemia, irritation, Conjunctivitis, Vision blurred, Sleep disorder. reveals various associated newly identified risks. Future research needs delve deeper into safety better guide its clinical application.

Language: Английский

Citations

0
PROPHYLACTIC KETAMINE: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS DOI
Astrid M. Cardona-Acosta, Lyonna F. Parise,

Carlos A. Bolaños‐Guzmán

et al.

Biological Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Chronic, combinatorial targeting of NMDARs and 5-HT4Rs exerts extended behavioral effects against stress-induced perseverative behavior and hyponeophagia DOI
Briana K. Chen, Alicia R Whye,

Louise C Matthews

et al.

Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

Language: Английский

Citations

0